Lorus Therapeutics Announces Allowance of Chinese Patent for Anticancer Drug LOR-253

Tue Mar 5, 2013 7:00am EST

* Reuters is not responsible for the content in this press release.

Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company
specializing in the discovery, research and development of pharmaceutical
products and technologies for the management of cancer, today announced
that Lorus' patent for its lead small molecule anticancer drug LOR-253
has been allowed in China. The patent provides Lorus with exclusive
rights to LOR-253 in China until 2026.

    The Chinese patent provides composition of matter protection for LOR-253
and for use in the manufacture of therapies for the treatment of cancer.
The patent covers a wide range of cancers, including leukemia, melanoma,
as well as non-small cell lung, colon, prostate, and breast tumors. This
patent extends the Company's international patent portfolio which
includes similar protection for LOR-253 in the United States, Canada, and
Australia. Applications are pending in Europe and Japan.

    "This increased patent protection for our anticancer therapies supports
our business discussions with potential partners," said Dr. Aiping Young,
Lorus' President and CEO. "This Chinese patent is an important addition
to our global IP portfolio for LOR-253, and demonstrates our commitment
to the development of innovative cancer therapies intended for
significant markets." 

    LOR-253 is currently in a clinical study at Memorial Sloan Kettering
Cancer Center and MD Anderson Cancer Center evaluating tumor biomarkers
in biopsy-suitable patients with advanced or metastatic solid tumors. 

    About LOR-253 

    LOR-253 represents a new class of anticancer agent, which we believe may
offer a competitive advantage over conventional drugs. This drug
candidate has shown selective and potent antitumor activity in
preclinical investigations with a variety of human cancers, including
colon cancer and non-small cell lung cancer, and has demonstrated an
excellent therapeutic window due to its low toxicity. LOR-253 is a
first-in-class small molecule that has been optimized to induce the novel
tumor suppressor Kruppel-like factor 4 (KLF4), leading to cancer cell
cycle arrest and apoptosis as well as inhibition of metastasis.

    About Lorus 

    Lorus is a biopharmaceutical company focused on the discovery, research
and development of novel therapeutics in cancer. Lorus' goal is to
capitalize on its research, preclinical, clinical and regulatory
expertise by developing new drug candidates that can be used, either
alone, or in combination with other drugs, to successfully manage cancer.
The Company also has expertise in antimicrobial drug discovery. Lorus
Therapeutics Inc. is listed on the Toronto Stock Exchange under the
symbol LOR.

    Forward-Looking Statements 

    This press release may contain forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include,
but are not limited to, statements relating to: our research program
plans, our plans to conduct clinical trials, the successful and timely
completion of clinical studies and the regulatory approval process, our
ability to continue as a going concern, our ability to fund future
research, the Company's plans, objectives, expectations and intentions
and other statements including words such as "continue", "believe",
"plan", "expect", "intend", "will", "should", "may", and other similar
expressions. Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that, while
considered reasonable by us are inherently subject to significant
business, economic, competitive, political and social uncertainties and
contingencies. Many factors could cause our actual results, performance
or achievements to be materially different from any future results,
performance, or achievements that may be expressed or implied by such
forward-looking statements, including, among others: our ability to
continue as a going concern, our ability to obtain the capital required
for research and operations, the inherent risks in early stage drug
development including demonstrating efficacy, development time/cost and
the regulatory approval process; the progress of our clinical trials; our
ability to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market conditions;
and other risks detailed from time-to-time in our ongoing quarterly
filings, annual information forms, annual reports and annual filings with
Canadian securities regulators and the United States Securities and
Exchange Commission. 

    Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our
Annual Information Form underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of this
press release and we do not intend, and do not assume any obligation, to
update these forward-looking statements, except as required by law. We
cannot assure you that such statements will prove to be accurate as
actual results and future events could differ materially from those
anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance and
accordingly investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein. 

    Lorus Therapeutics Inc.'s recent press releases are available through the
Company's website at www.lorusthera.com. For Lorus' regulatory filings on
SEDAR, please go to www.Sedar.com. 

Lorus Therapeutics Inc.
Grace Tse
416-798-1200 ext. 380

The Trout Group
Lee M. Stern

Copyright 2013, Market Wire, All rights reserved.